Use of Anti – VEGF Therapy for ROP: When and How

Related

• 

  Long-term Complications of Laser Treated Infants With Retinopathy of Prematurity

  Audina M. Berrocal, MD FASRS

  Updates from the Field

  2020

• 

  Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept

  Mark R. Barakat, MD

  Annual Meeting Talks

  2022

• 

  Clinical Feasibility of Ultra-rapid, Non-pharmacologic Anesthesia for Intravitreal Injection in Patients Receiving Anti-VEGF Treatment

  Cagri G Besirli, MD, PhD, FASRS

  Annual Meeting Talks

  2018